Appendix 1—table 2. Drug effects on the exploration bonus parameter ($\phi$) on the group-level.

	${\mathrm{{\rm M}}}^{\phi }$		${\mathrm{\Lambda }}^{\phi }$
	% above 0	90% HDI	% above 0	90% HDI
placebo - L-dopa	97.5	[0.05, 0.69]	47.5	[−0.18, 0.16]
placebo - haloperidol	49.3	[−0.30, 0.27]	90.0	[−0.04, 0.29]
L-dopa - haloperidol	1.7	[−0.70,–0.10]	90.8	[−0.02, 0.31]

Note: Results refer to the posterior drug differences of the group-level mean (${\mathrm{{\rm M}}}^{\mathrm{\phi }}$) and standard deviation (${\mathrm{\Lambda }}^{\mathrm{\phi }}$) for the $\mathrm{\phi }$ parameter of the winning model. For each posterior difference, the table shows the percentage of samples with values above zero (column: % above 0) and the 90% highest density interval (column: 90%HDI).